Anastasia Khvorova, Ph.D., has over 20 years of experience developing oligonucleotide technology and therapeutics. She is the Remondi Family Chair in Biomedical Sciences and professor at the RNA Therapeutics Institute and Program in Molecular Medicine at the University of Massachusetts (UMass) Chan Medical School. Her lab combines hardcore organic and oligonucleotide chemists with RNA biologists and pharmacologists to develop novel approaches and solutions to understanding natural and therapeutic RNA trafficking and delivery. Dr. Khvorova founded the UMass Nucleic Acid Chemistry Center, the only nonprofit facility in North America with expertise and capacity for complex RNA molecule synthesis at scale and numbers. Dr Khvorova’s laboratory has trained dozens of next-generation scientists expanding the progress of oligonucleotide therapeutics in North America and worldwide.

Before UMass Chan Medical School, Dr. Khvorova spent 12 years in industry in different executive positions. She has co-founded several biotechnology companies.

Dr. Khvorova is a National Academy of Inventors member with more than 150 patents and 300 patent applications. She has authored more than 100 peer-reviewed publications, including seminal articles in Cell, Nature, and Nature Biotechnology, defining the field of RNAi drug design and development. She has served as one of the early directors of the Oligonucleotide Therapeutics Society and as a Director-at-Large, and Scientific & Research Council Chair of the American Society of Gene and Cell Therapy.

AFFILIATIONS:

• ASGCTDirector at large(2020-2023)
• Editor (NAR, MTNA, NAT)
• SAB (Atalanta, Evox, Comanche, Alltrna, Prime Medicine, Aldena)